Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cybin ( (TSE:CYBN) ) has provided an update.
Cybin announced its participation in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, with key executives engaging in a fireside chat. This participation underscores Cybin’s commitment to advancing neuropsychiatric treatments and highlights its strategic positioning in the mental health industry, potentially impacting stakeholders by showcasing its innovative drug pipeline.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a late-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is advancing novel drugs for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
See more insights into CYBN stock on TipRanks’ Stock Analysis page.